Drug & intervention

flutamide

RxCUI 4508

Clinical trials44
Recruiting1
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Flutamide

Flutamide, sold under the brand name Eulexin among others, is a nonsteroidal antiandrogen (NSAA) which is used primarily to treat prostate cancer. It is also used in the treatment of androgen-dependent conditions like acne, excessive hair growth, and high androgen levels in women. It is taken by mouth, usually three times per day. Side effects in men include breast tenderness and enlargement, feminization, sexual dysfunction, and hot flashes. Conversely, the medication has fewer side effects and is better-tolerated in women with the most common side effect being dry skin. Diarrhea and elevated liver enzymes can occur in both sexes. Rarely, flutamide can cause liver damage, lung disease, sensitivity to light, elevated methemoglobin, elevated sulfhemoglobin, and deficient neutrophils. Numerous cases of liver failure and death have been reported, which has limited the use of flutamide. Flutamide acts as a selective antagonist of the androgen receptor (AR), competing with androgens like testosterone and dihydrotestosterone (DHT) for binding to ARs in tissues like the prostate gland. By doing so, it prevents their effects and stops them from stimulating prostate cancer cells to grow. Flutamide is a prodrug to a more active form. Flutamide and its active form stay in the body for a relatively short time, which makes it necessary to take flutamide multiple times per day. Flutamide was first described in 1967 and was first introduced for medical use in 1983. It became available in the United States in 1989. The medication has largely been replaced by newer and improved NSAAs, na...

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerNCT03678025 · 2018-09-24
RECRUITING
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialNCT05050084 · 2021-12-06
ACTIVE_NOT_RECRUITING
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT04513717 · 2021-01-21
ACTIVE_NOT_RECRUITING
Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer PatientsNCT04248621 · 2020-01-23
UNKNOWN
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen SuppressionNCT03507608 · 2019-05-10
COMPLETED
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by SurgeryNCT03070886 · 2017-04-05
ACTIVE_NOT_RECRUITING
Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate CancerNCT02918968 · 2016-11-02
COMPLETED
Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)NCT02742675 · 2015-09-01
UNKNOWN
Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.NCT02346578 · 2014-12-01
COMPLETED
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate CancerNCT01786265 · 2013-02-05
ACTIVE_NOT_RECRUITING
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate CancerNCT00936390 · 2009-09-01
COMPLETED
Effects of Flutamide on Insulin and Glucose Metabolism in Women With Polycystic Ovary SyndromeNCT00729560 · 2008-07-01
TERMINATED
Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate CancerNCT00651326 · 2008-06-02
TERMINATED
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical ProstatectomyNCT00528866 · 2008-04-01
COMPLETED
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate CancerNCT00512668 · 2007-09-01
TERMINATED
External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate CancerNCT00388804 · 2005-02-01
TERMINATED
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate CancerNCT00170157 · 2004-06-01
COMPLETED
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate AdenocarcinomaNCT01011751 · 2004-04-01
COMPLETED
Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer.NCT06601205 · 2004-01-01
COMPLETED
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate CancerNCT00104741 · 2003-09-10
COMPLETED
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate CancerNCT00054106 · 2002-12-10
COMPLETED
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate CancerNCT00030654 · 2002-10-01
COMPLETED
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate CancerNCT00028769 · 2001-12-01
COMPLETED
SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate CancerNCT00026377 · 2001-11-01
COMPLETED
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate CancerNCT00023829 · 2001-08-01
COMPLETED
Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the ProstateNCT00006214 · 2000-08-01
COMPLETED
Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate CancerNCT01122121 · 2000-03-01
COMPLETED
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate CancerNCT00004054 · 2000-01-01
COMPLETED
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for RecurrenceNCT00003645 · 1999-06-14
TERMINATED
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate CancerNCT00003653 · 1999-01-05
COMPLETED
Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate CancerNCT00003734 · 1998-12-01
UNKNOWN
Hormone Therapy in Treating Patients With Prostate CancerNCT00003323 · 1998-05-01
COMPLETED
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate CancerNCT00002889 · 1997-05-01
COMPLETED
Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate CancerNCT00003124 · 1997-05-01
COMPLETED
Hormone Therapy in Treating Patients With Advanced Prostate CancerNCT00003026 · 1997-04-01
COMPLETED
Effects of IAS in Men With Localized Biochemical Relapsed Prostate CancerNCT00223665 · 1997-01-08
COMPLETED
Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,cNCT00817739 · 1996-12-01
COMPLETED
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate CancerNCT00002881 · 1996-10-01
COMPLETED
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate CancerNCT00002855 · 1996-08-01
COMPLETED
Radiation Therapy and Hormone Therapy in Treating Patients With Prostate CancerNCT00769548 · 1995-04-01
COMPLETED

Conditions being studied

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.